Blueprint Medicines BPMC reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
Blueprint Medicines missed estimated earnings by 20.18%, reporting an EPS of $-2.68 versus an estimate of $-2.23.
Revenue was up $9.25 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.15 which was followed by a 0.7% increase in the share price the next day.
Here’s a look at Blueprint Medicines’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -1.94 | -1.65 | -1.63 | -1.86 |
| EPS Actual | -1.79 | -0.99 | -2 | -1.86 |
| Revenue Estimate | 36.65M | 102.69M | 42.47M | 19.01M |
| Revenue Actual | 62.73M | 107.02M | 24.19M | 27.30M |
To track all earnings releases for Blueprint Medicines visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Image and article originally from www.benzinga.com. Read the original article here.